<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Acitretin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00459</strong>&#160; (APRD00778)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00459/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00459/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00459.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00459.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00459.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00459.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00459.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00459">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Acetretin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Neotigason</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Soriatane</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/keratolytic-agents">Keratolytic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>55079-83-9</td></tr><tr><th>Weight</th><td>Average: 326.4293<br>Monoisotopic: 326.188194698</td></tr><tr><th>Chemical Formula</th><td>C<sub>21</sub>H<sub>26</sub>O<sub>3</sub></td></tr><tr><th>InChI Key</th><td>IHUNBGSDBOWDMA-AQFIFDHZSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=C(C)C(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Prenol Lipids</td></tr><tr><th>Subclass</th><td>Retinoids</td></tr><tr><th>Direct parent</th><td>Retinoids</td></tr><tr><th>Alternative parents</th><td>Sesquiterpenes; Carbocyclic Fatty Acids; Styrenes; Anisoles; Toluenes; Branched Fatty Acids; Alkyl Aryl Ethers; Unsaturated Fatty Acids; Enones; Carboxylic Acids; Polyamines; Enolates</td></tr><tr><th>Substituents</th><td>cyclofarsesane sesquiterpene; phenol ether; styrene; anisole; alkyl aryl ether; toluene; benzene; enone; polyamine; carboxylic acid; carboxylic acid derivative; ether; enolate</td></tr><tr><th>Classification description</th><td>This compound belongs to the retinoids. These are compounds that are related to vitamin A, especially retinol.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of severe psoriasis in adults.</td></tr><tr><th>Pharmacodynamics</th><td>Acitretin is a retinoid. Retinoids have a structure similar to vitamin A and are involved in the normal growth of skin cells. Acitretin works by inhibiting the excessive cell growth and keratinisation (process by which skin cells become thickened due to the deposition of a protein within them) seen in psoriasis. It therefore reduces the thickening of the skin, plaque formation and scaling.</td></tr><tr><th>Mechanism of action</th><td>The mechanism of action of acitretin is unknown, however it is believed to work by targeting specific receptors (retinoid receptors such as RXR and RAR) in the skin which help normalize the growth cycle of skin cells.</td></tr><tr><th>Absorption</th><td>Oral absorption of acitretin is optimal when given with food, and is linear and proportional with increasing doses from 25 to 100 mg. Approximately 72% (range 47% to 109%) of the administered dose was absorbed after a single 50 mg dose of acitretin was given to 12 healthy subjects.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Over 99.9% bound to plasma proteins, primarily albumin.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Following oral absorption, acitretin undergoes extensive metabolism and interconversion by simple isomerization to its 13-cis form (cis-acitretin). Both parent compound and isomer are further metabolized into chain-shortened breakdown products and conjugates, which are excreted.</p></td></tr><tr><th>Route of elimination</th><td>Both parent compound and isomer are further metabolized into chain-shortened breakdown products and conjugates, which are excreted.  The chain-shortened metabolites and conjugates of acitretin and cis-acitretin are ultimately excreted in the feces (34% to 54%) and urine (16% to 53%).</td></tr><tr><th>Half life</th><td>49 hours (range 33 to 96 hours)</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Oral, rat: LD<sub>50</sub> = &gt;4000 mg/kg. Symptoms of overdose include headache and vertigo.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Adverse Reaction</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Apolipoprotein E<br>Gene symbol: APOE<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P02649" target="_blank">P02649 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs429358" target="_blank">rs429358 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>C allele</td><td>Psoriasis</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16433808" target="_blank" title="Campalani E, Allen MH, Fairhurst D, Young HS, Mendonca CO, Burden AD, Griffiths CE, Crook MA, Barker JN, Smith CH: Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol. 2006 Feb;154(2):345-52.">16433808 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Apolipoprotein E<br>Gene symbol: APOE<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P02649" target="_blank">P02649 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs7412" target="_blank">rs7412 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>C allele</td><td>Psoriasis</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16433808" target="_blank" title="Campalani E, Allen MH, Fairhurst D, Young HS, Mendonca CO, Burden AD, Griffiths CE, Crook MA, Barker JN, Smith CH: Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol. 2006 Feb;154(2):345-52.">16433808 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9885</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.5841</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8628</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.6057</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6973</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9382</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8899</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8202</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5108</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6804</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9239</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9409</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.648</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8768</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.5923</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8341
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.83
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.714
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.8804 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9216
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9501
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Stiefel laboratories inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.pharm-int.com">Pharmaceutics International Inc.</a></li>
<li><a href="http://www.stiefel.com">Stiefel Labs</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00618">Demeclocycline</a></td><td>Increased risk of intracranial hypertension</td></tr><tr><td><a href="/drugs/DB00254">Doxycycline</a></td><td>Increased risk of intracranial hypertension</td></tr><tr><td><a href="/drugs/DB00931">Methacycline</a></td><td>Increased risk of intracranial hypertension</td></tr><tr><td><a href="/drugs/DB00563">Methotrexate</a></td><td>Acitretin/etretinate increases the effect and toxicity of methotrexate</td></tr><tr><td><a href="/drugs/DB01017">Minocycline</a></td><td>Increased risk of intracranial hypertension.</td></tr><tr><td><a href="/drugs/DB00717">Norethindrone</a></td><td>Acitretine may cause a loss of contraceptive effect</td></tr><tr><td><a href="/drugs/DB00595">Oxytetracycline</a></td><td>Increased risk of intracranial hypertension</td></tr><tr><td><a href="/drugs/DB01301">Rolitetracycline</a></td><td>Increased risk of intracranial hypertension</td></tr><tr><td><a href="/drugs/DB00759">Tetracycline</a></td><td>Increased risk of intracranial hypertension</td></tr><tr><td><a href="/drugs/DB00162">Vitamin A</a></td><td>Acitretin increases the risk of vitamin A toxicity. Avoid vitamin A supplementation while taking acitretin. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>